logo

TFFP(Delisted)

TFF Pharmaceuticals·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 0
Revenue Beats Expectation
EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About TFFP

Tff Pharmaceuticals, Inc.

A biotech company developing and commercializing innovative inhalation products for lung diseases and conditions

--
01/24/2018
10/25/2019
NASDAQ Stock Exchange
19
12-31
Common stock
1751 River Run, Suite 400, Fort Worth, Texas 76107
--
TFF Pharmaceuticals, Inc., was incorporated in Delaware on January 24, 2018. The company is an early stage biopharmaceutical company focused on developing and commercializing innovative drugs based on its patented thin film freezing (TFF) technology platform. The company's early tests confirmed that the TFF platform can significantly improve the solubility of poorly water-soluble drugs, which account for about 40% of the world's major drugs, thereby improving the pharmacokinetic effects of these drugs.

Company Financials

EPS

TFFP has released its 2024 Q2 earnings. EPS was reported at -1.22, versus the expected -1.7, beating expectations. The chart below visualizes how TFFP has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TFFP has released its 2024 Q3 earnings report, with revenue of 193.39K, reflecting a YoY change of -17.62%, and net profit of -3.54M, showing a YoY change of 19.60%. The Sankey diagram below clearly presents TFFP's revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime

No Data